Trial Profile
Study of the Safety and Efficacy of LY2623091 in Chronic Kidney Disease Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs LY 2623091 (Primary) ; Eplerenone
- Indications Kidney disorders
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 01 Feb 2017 Results (n=294) assessing population pharmacokinetics of LY-2623091 using patients data from this and other four trials (NCT02194465, NCT02242981, NCT01237899), published in the Journal of Clinical Pharmacology
- 28 Apr 2014 New trial record